Search results for "Adrenergic"

showing 10 items of 433 documents

Quality control of pharmaceuticals containing clenbuterol by thermal lens spectrometry.

1996

An ultrasensitive absorptiometric procedure for the determination of clenbuterol in pharmaceutical preparations was developed. Clenbuterol was diazotized with nitrite and coupled with 1-(naphthyl)ethylenediamine, and the absorbance of the azo dye formed was measured by both spectrophotometry and ultrasensitive thermal lens spectrometry (TLS). The TLS limit of detection was 1.5 ppb, 14-fold lower than with a Hewlett-Packard diode array spectrophotometer. Thus, the TLS procedure can be advantageously applied to quality control of clenbuterol at the individual dose level and in small samples. Repeatability as relative standard deviation was 1.5% (50 ppb, n = 6).

Detection limitQuality ControlChromatographymedicine.diagnostic_testClinical BiochemistryPharmaceutical ScienceRepeatabilityAdrenergic beta-AgonistsMass spectrometryAnalytical ChemistryAbsorbancechemistry.chemical_compoundchemistryClenbuterolSpectrophotometryDrug DiscoverymedicineClenbuterolSpectrophotometry UltravioletDerivatizationQuantitative analysis (chemistry)Spectroscopymedicine.drugTabletsJournal of pharmaceutical and biomedical analysis
researchProduct

Alpha 1 adrenoceptor expression in skin, nerves and blood vessels of patients with painful diabetic neuropathy

2021

Abstract Diabetic neuropathy (dNP) patients often suffer from severe neuropathic pain. It was suggested that alpha-1 adrenoceptor (α1-AR) hyperresponsiveness contributes to pain in dNP. The aim of our study was to quantify α1-AR expression using immunohistochemistry in skin biopsies of nine patients with painful diabetic neuropathy compared to 10 healthy controls. Additionally, the association between α1-AR expression and activation with spontaneous and sympathetically maintained pain (SMP) induced by intradermal injection of the α1-agonist phenylephrine was investigated. For control purposes the α2-agonist clonidine was injected in a different session. We found that dermal nerve density wa…

Diabetic neuropathyAdrenergic receptorPainPhenylephrine03 medical and health sciencesCellular and Molecular Neuroscience0302 clinical medicineDiabetic NeuropathiesReceptors Adrenergic alpha-1Diabetes MellitusmedicineHumansIntradermal injectionReceptorPhenylephrineSkinEndocrine and Autonomic Systemsbusiness.industrymedicine.diseaseClonidineAnesthesiaNeuropathic painImmunohistochemistryNeurology (clinical)business030217 neurology & neurosurgerymedicine.drugAutonomic Neuroscience
researchProduct

takotsubo cardiomiopathy after acute diarrhea

2010

Takotsubo cardiomyopaty is a recently described syndrome characterized by transient left ventricular dysfunction, mimicking an acute coronary syndrome and usually precipitated by a physical or emotional stress. We report the first case of Takotsubo cardiomyopathy after acute diarrhea in a man. It may be argued that severe diarrhea in predisposed individuals may cause an acute stress resulting in increased sympathetic activity leading to this syndrome. Probably the relationship between the adrenergic system and the heart is more complex than general thought and the stimuli which favor an autonomic imbalance and precipitate the syndrome are very disparate in clinical practice.

DiarrheaMalemedicine.medical_specialtyAcute diarrheaAcute coronary syndromeCardiomyopathyAdrenergicDiagnosis DifferentialElectrocardiographyTakotsubo CardiomyopathyInternal medicineInternal MedicineMedicineHumansAcute Coronary Syndrometakotsubo cardiomiopathyAgedmedicine.diagnostic_testbusiness.industryGeneral Medicinemedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareDiarrheaEndocrinologyEchocardiographyAutonomic imbalanceAcute DiseaseCardiologymedicine.symptomDifferential diagnosisbusinessElectrocardiography
researchProduct

Pharmacological distribution diagrams: a tool for de novo drug design.

1996

Abstract Discriminant analysis applied to SAR studies using topological descriptors allows us to plot frequency distribution diagrams: a function of the number of drugs within an interval of values of discriminant function vs. these values. We make use of these representations, pharmacological distribution diagrams (PDDs), in structurally heterogeneous groups where generally they adopt skewed Gaussian shapes or present several maxima. The maxima afford intervals of discrimianant function in which exists a good expectancy to find new active drugs. A set of β-blockers with contrasted activity has been selected to test the ability of PDDs as a visualizing technique, for the identification of n…

Distribution (number theory)GaussianAdrenergic beta-AntagonistsBiophysicsInterval (mathematics)Machine learningcomputer.software_genreBiochemistryPlot (graphics)symbols.namesakeDiscriminant function analysisComputer GraphicsPharmacokineticsMathematicsMolecular Structurebusiness.industryDiscriminant AnalysisPattern recognitionFunction (mathematics)Linear discriminant analysisDrug DesignsymbolsArtificial intelligenceMaximabusinesscomputerHalf-LifeJournal of molecular graphics
researchProduct

Anti-adrenergic effects of ranolazine in isolated rat aorta

2014

Ranolazine, a piperazine derivative, is used as an anti- anginal drug to treat patients with chronic angina in clinical practice [1] and may improve coronary blood flow by reducing compression effects of ischemic contracture, and by improving endothelial function [2],[3]. In the present study we investigate the vascular effects of ranolazine on the endothelium, adrenergic system and Ca2+ in isolated rat aorta.

DrugAortaEndotheliumbusiness.industrymedia_common.quotation_subjectRanolazineAdrenergicChronic anginaBlood flowIschemic ContracturePharmacologyCritical Care and Intensive Care Medicinemedicine.anatomical_structuremedicine.arteryPoster Presentationmedicinebusinessmedicine.drugmedia_commonCritical Care
researchProduct

Preclinical evidence of new opioid modulators for the treatment of addiction.

2010

Addiction to opiates is one of the most severe forms of substance dependence, and despite a variety of pharmacological approaches to treat it, relapse is observed in a high percentage of subjects. New pharmacological compounds are necessary to improve the outcome of treatments and reduce adverse side effects. Moreover, drugs that act on the opioid system can also be of benefit in the treatment of alcohol or cocaine addiction. AREA COVERED BY THIS REVIEW: Recent preclinical studies of pharmacological agents for the treatment of opiate addiction (2008 to the present date).The reader will be informed of the latest drugs shown in animal models to modify dependence on opiates and the reinforcing…

DrugGABA Agentsmedia_common.quotation_subjectNarcotic AntagonistsDrug Evaluation PreclinicalReceptors Opioid muPharmacologyReceptors NicotinicBioinformaticsPharmacotherapyDopamineReceptors Opioid deltaCannabinoid Receptor ModulatorsmedicineAdrenergic alpha-2 Receptor AgonistsAnimalsPharmacology (medical)Adverse effectmedia_commonPharmacologySubstance dependencebusiness.industryAddictionReceptors Opioid kappaAntagonistGeneral Medicinemedicine.diseaseOpioid-Related DisordersRatsSubstance Withdrawal SyndromeOpioidReceptors OpioidDopamine AntagonistsFemalebusinessExcitatory Amino Acid Antagonistsmedicine.drugExpert opinion on investigational drugs
researchProduct

Characterization of basic drug–human serum protein interactions by capillary electrophoresis

2006

Drug-protein interactions are determining factors in the therapeutic, pharmacodynamic and toxicological drug properties. The affinity of drugs towards plasmatic proteins is apparently well established in bibliography. Albumin (HSA) especially binds neutral and negatively charged compounds; alpha(1)-acid glycoprotein (AGP) binds many cationic drugs, lipoproteins bind to nonionic and lipophilic drugs and some anionic drugs while globulins interact inappreciably with the majority of drugs. In this paper, the characterization of the interaction between cationic drugs, beta-blockers and phenotiazines towards HSA, AGP, and both HSA + AGP mixtures of proteins under physiological conditions by CE-f…

DrugGlobulinmedia_common.quotation_subjectAdrenergic beta-AntagonistsClinical BiochemistryThiazinesUltrafiltrationPlasma protein bindingBiochemistryAnalytical ChemistryCapillary electrophoresisPhenothiazinesmedicineHumansLabetalolSerum Albuminmedia_commonchemistry.chemical_classificationbiologyAlbuminElectrophoresis CapillaryBlood ProteinsOrosomucoidHuman serum albuminchemistryBiochemistryPindololbiology.proteinGlycoproteinDrug metabolismProtein Bindingmedicine.drugELECTROPHORESIS
researchProduct

Structural effects and neurofunctional sequelae of developmental exposure to psychotherapeutic drugs: experimental and clinical aspects

2004

The advent of psychotherapeutic drugs has enabled management of mental illness and other neurological problems such as epilepsy in the general population, without requiring hospitalization. The success of these drugs in controlling symptoms has led to their widespread use in the vulnerable population of pregnant women as well, where the potential embryotoxicity of the drugs has to be weighed against the potential problems of the maternal neurological state. This review focuses on the developmental toxicity and neurotoxicity of five broad categories of widely available psychotherapeutic drugs: the neuroleptics, the antiepileptics, the antidepressants, the anxiolytics and mood stabilizers, an…

Drugmedicine.medical_specialtymedia_common.quotation_subjectPopulationDevelopmental toxicityserotonin-reuptake inhibitorsEpilepsyNeurochemicalmedicineAnimalsHumansprenatal phenytoin exposurePsychiatryeducationbeta-adrenergic-receptorsmedia_commonPharmacologyrat-brain developmentPsychotropic Drugseducation.field_of_studybusiness.industryMental DisordersNeurotoxicityBrainbeta-adrenergic-receptors; central-nervous-system; cerebellar granule cells; developing cerebral-cortex; fetal hydantoin syndrome; messenger-rna expression; prenatal phenytoin exposure; rat-brain development; serotonin-reuptake inhibitors; st-johns-wortmedicine.diseaseMental illnessdeveloping cerebral-cortexmessenger-rna expressionMoodcerebellar granule cellsMolecular Medicinecentral-nervous-systemPlant Preparationsst-johns-wortfetal hydantoin syndromebusiness
researchProduct

LABA/LAMA fixed-dose combinations in patients with COPD: A systematic review

2018

Paola Rogliani,1 Luigino Calzetta,1 Fulvio Braido,2 Mario Cazzola,1 Enrico Clini,3 Girolamo Pelaia,4 Andrea Rossi,5 Nicola Scichilone,6 Fabiano Di Marco7 1Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy; 2Department of Internal Medicine, IRCCS San Martino Genoa University Hospital, Genoa, Italy; 3Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy; 4Department of Medical and Surgical Sciences, Section of Respiratory Diseases, Magna Græcia University, Catanzaro, Italy; 5Pulmonary Unit, University of Verona, Verona, Italy; 6Department of Internal Medicine, University of Palermo, Palermo, Italy; 7…

ExacerbationReviewQuinoloneslaw.inventionPulmonary Disease Chronic Obstructivechemistry.chemical_compound0302 clinical medicineRandomized controlled trialsystematic reviewlaw030212 general & internal medicineCOPDLABA LAMA fixed-dose combination COPD systematic reviewbiologyHealth PolicyOlodaterolLAMAGeneral MedicineLamaRespiratory Function Testsfixed-dose combinationDrug CombinationsTreatment OutcomeIndanssystematic review.hormones hormone substitutes and hormone antagonistsmedicine.drugPulmonary and Respiratory Medicinemedicine.medical_specialtyFixed-dose combinationLABA; LAMA; fixed-dose combination; COPD; systematic reviewLABAMuscarinic AntagonistsSettore MED/10 - Malattie Dell'Apparato Respiratorio03 medical and health sciencesInternal medicinemedicineHumansCOPDAdverse effectAdrenergic beta-2 Receptor Agonistslcsh:RC705-779business.industryPublic Health Environmental and Occupational Healthlcsh:Diseases of the respiratory systemCOPD; LABA; LAMA; fixed-dose combination; systematic reviewmedicine.diseasebiology.organism_classificationGlycopyrrolate030228 respiratory systemchemistryDelayed-Action PreparationsIndacaterolbusiness
researchProduct

Synthesis and preliminary evaluation of (R,R)(S,S) 5-(2-(2-[4-(2-[18F]fluoroethoxy)phenyl]-1-methylethylamino)-1-hydroxyethyl)-benzene-1,3-diol ([18F…

2003

The 18 F-labeled b2-adrenergic receptor ligand (R,R)(S,S) 5-(2-(2-(4-(2-( 18 F)fluoroethoxy)phenyl)-1-methylethylamino)-1- hydroxyethyl)-benzene-1,3-diol, a derivative of the original highly selective racemic fenoterol, was synthesized in an overall radio- chemical yield of 20% after 65 min with a radiochemical purity higher than 98%. The specific activity was in the range of 50-60 GBq/mmol. In vitro testing of the non-radioactive fluorinated fenoterol derivative with isolated guinea pig trachea was conducted to obtain an IC50 value of 60 nM. Preliminary ex vivo organ distribution and in vivo experiments with positron emission tomography (PET) on guinea pigs were performed to study the biod…

Fluorine RadioisotopesBiodistributionSwineStereochemistryClinical BiochemistryDiolPharmaceutical ScienceIn Vitro TechniquesBiochemistryChemical synthesisGuinea pigchemistry.chemical_compoundIn vivoDrug DiscoverymedicineAnimalsTissue DistributionLungMolecular BiologyFenoterolFenoterolOrganic ChemistryLigand (biochemistry)Models ChemicalchemistryMolecular MedicineReceptors Adrenergic beta-2RadiopharmaceuticalsEx vivoTomography Emission-Computedmedicine.drugBioorganic & Medicinal Chemistry Letters
researchProduct